Terms: = Colorectal cancer AND PSA AND Prognosis
20 results:
1. The survival of the prostate cancer patients with secondary colorectal cancer: a study based on a SEER database from southern China.
Lin L; Huang L; Li YL; Shan H
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1128-1133. PubMed ID: 36808373
[TBL] [Abstract] [Full Text] [Related]
2. Postoperative complications are associated with poor survival outcome after curative resection for colorectal cancer: A propensity-score analysis.
Miyamoto Y; Hiyoshi Y; Tokunaga R; Akiyama T; Daitoku N; Sakamoto Y; Yoshida N; Baba H
J Surg Oncol; 2020 Aug; 122(2):344-349. PubMed ID: 32346880
[TBL] [Abstract] [Full Text] [Related]
3. Validation of a subclassification for high-risk prostate cancer in a prospective cohort.
Butler SS; Dee EC; Lamba N; Sha ST; Mahal BA; Whitbeck A; Makkar R; Wangoe J; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2020 May; 126(10):2132-2138. PubMed ID: 32073662
[TBL] [Abstract] [Full Text] [Related]
4. Early Epigenetic Markers for Precision Medicine.
Dumitrescu RG
Methods Mol Biol; 2018; 1856():3-17. PubMed ID: 30178243
[TBL] [Abstract] [Full Text] [Related]
5. Sigmoid Colon Adenocarcinoma with Isolated Loss of PMS2 Presenting in a Patient with Synchronous Prostate cancer with Intact MMR: Diagnosis and Analysis of the Family Pedigree.
Liu W; Zhang D; Tan SA; Liu X; Lai J
Anticancer Res; 2018 Aug; 38(8):4847-4852. PubMed ID: 30061258
[TBL] [Abstract] [Full Text] [Related]
6. Identifying cancer origin using circulating tumor cells.
Lu SH; Tsai WS; Chang YH; Chou TY; Pang ST; Lin PH; Tsai CM; Chang YC
Cancer Biol Ther; 2016 Apr; 17(4):430-8. PubMed ID: 26828696
[TBL] [Abstract] [Full Text] [Related]
7. Altered Activity and Expression of Cytosolic Peptidases in colorectal cancer.
Perez I; Blanco L; Sanz B; Errarte P; Ariz U; Beitia M; Fernández A; Loizate A; Candenas ML; Pinto FM; Gil J; López JI; Larrinaga G
Int J Med Sci; 2015; 12(6):458-67. PubMed ID: 26078706
[TBL] [Abstract] [Full Text] [Related]
8. If you have an active vagus nerve, cancer stage may no longer be important.
Gidron Y; De Couck M; De Greve J
J Biol Regul Homeost Agents; 2014; 28(2):195-201. PubMed ID: 25001652
[TBL] [Abstract] [Full Text] [Related]
9. Predictions for the future of kallikrein-related peptidases in molecular diagnostics.
Scorilas A; Mavridis K
Expert Rev Mol Diagn; 2014 Jul; 14(6):713-22. PubMed ID: 24927162
[TBL] [Abstract] [Full Text] [Related]
10. Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications.
Harouaka R; Kang Z; Zheng SY; Cao L
Pharmacol Ther; 2014 Feb; 141(2):209-21. PubMed ID: 24134902
[TBL] [Abstract] [Full Text] [Related]
11. [Prostate cancer in Luxembourg from 1982 to 2006. Incidence and mortality. Survival of a hospital cohort].
Lamy S; Wilmart JF; Hein T; Scheiden R; Capesius C
Bull Soc Sci Med Grand Duche Luxemb; 2013; (1):6-19. PubMed ID: 23808106
[TBL] [Abstract] [Full Text] [Related]
12. Clinical significance of kallikrein-related peptidase (KLK10) mRNA expression in colorectal cancer.
Alexopoulou DK; Papadopoulos IN; Scorilas A
Clin Biochem; 2013 Oct; 46(15):1453-61. PubMed ID: 23499583
[TBL] [Abstract] [Full Text] [Related]
13. High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.
Jonsson L; Gaber A; Ulmert D; Uhlén M; Bjartell A; Jirström K
Diagn Pathol; 2011 Sep; 6():91. PubMed ID: 21955582
[TBL] [Abstract] [Full Text] [Related]
14. Penile metastasis from adenocarcinoma of the prostate in a patient with colorectal carcinoma.
Yildiz B; Fidan E; Yildiz K; Aydin F
Acta Dermatovenerol Croat; 2011; 19(1):36-8. PubMed ID: 21489365
[TBL] [Abstract] [Full Text] [Related]
15. Effect of human colorectal carcinogenesis on the neural cell adhesion molecule expression and polysialylation.
Fernández-Briera A; García-Parceiro I; Cuevas E; Gil-Martín E
Oncology; 2010; 78(3-4):196-204. PubMed ID: 20414008
[TBL] [Abstract] [Full Text] [Related]
16. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies.
Avgeris M; Mavridis K; Scorilas A
Biol Chem; 2010 May; 391(5):505-11. PubMed ID: 20302518
[TBL] [Abstract] [Full Text] [Related]
17. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
[TBL] [Abstract] [Full Text] [Related]
18. Distinguishing prostatic from colorectal adenocarcinoma on biopsy samples: the role of morphology and immunohistochemistry.
Owens CL; Epstein JI; Netto GJ
Arch Pathol Lab Med; 2007 Apr; 131(4):599-603. PubMed ID: 17425391
[TBL] [Abstract] [Full Text] [Related]
19. [Ganglion curage in prostate cancer].
Schumacher M; Burkhard FC; Studer UE
Ann Urol (Paris); 2005 Oct; 39(5):197-202. PubMed ID: 16370170
[TBL] [Abstract] [Full Text] [Related]
20. Doctor's dilemma: incorporating tumor markers into clinical decision-making.
Canil CM; Tannock IF
Semin Oncol; 2002 Jun; 29(3):286-93. PubMed ID: 12063682
[TBL] [Abstract] [Full Text] [Related]
